Loading…
Loading…
EQUITY / NASDAQ · XNCM
Lexaria Bioscience Corp.
No accepted understanding yet. Follow this company to establish research where evidence supports it.
Open research workspace →03/01/2026 – 05/31/2026 · USD · Units
Reported figures establish facts for this period; they do not by themselves establish a profitability trend.
Open report ↗2.8666 USD · -0.4653%
Observed: Oct 2, 2026, 9:52 PM · TickerLayer indicative price; may be delayed
Powered by TickerLayer
10/02/2026 · 2.88 USD · Volume 81,266
250 actual observations · Latest bar: 2026-10-02 · Market data is indicative; provider terms apply.
8 available financial reports
Research reports →SEC FINANCIAL REPORTS
03/01/2026 – 05/31/2026 · Units
| Metric | 2026 / Quarter 3 | Prior year | Change |
|---|---|---|---|
| Revenue | 0 USD | — | — |
| Operating profit | -1,993,804 USD | — | — |
| Net income | -1,991,202 USD | — | — |
| Cash and cash equivalents | 3,500,000 USD | — | — |
| Total liabilities | 437,091 USD | — | — |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2026 / Quarter 303/01/2026 – 05/31/2026ConsolidatedUnits · USD | 2026 / Quarter 309/01/2025 – 05/31/2026ConsolidatedUnits · USD | 2026 / Quarter 312/01/2025 – 02/28/2026ConsolidatedUnits · USD | 2026 / Quarter 209/01/2025 – 02/28/2026ConsolidatedUnits · USD | 2026 / Quarter 309/01/2025 – 11/30/2025ConsolidatedUnits · USD | 2026 / Quarter 211/30/2025 – 11/30/2025ConsolidatedUnits · USD | 2025 / Quarter 308/31/2025 – 08/31/2025ConsolidatedUnits · USD | 2025 / Year end09/01/2024 – 08/31/2025ConsolidatedUnits · USD |
|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalentsBalance sheet | 3,500,000 USD | — | — | — | — | — | — | — |
| Gross profitIncome statement | 0 USD | 20,000 USD | — | 20,000 USD | — | — | — | 703,203 USD |
| Net incomeIncome statement | -1,991,202 USD | -5,036,188 USD | -1,449,979 USD | -3,044,986 USD | -1,595,007 USD | — | — | -11,901,841 USD |
| Operating profitIncome statement | -1,993,804 USD | -5,019,338 USD | — | -3,025,534 USD | — | — | — | -11,880,737 USD |
| RevenueIncome statement | 0 USD | 20,000 USD | — | 20,000 USD | — | — | — | 705,923 USD |
| Total assetsBalance sheet | 4,781,331 USD | — | — | — | — | — | 4,175,121 USD | 4,175,121 USD |
| Total equityBalance sheet | 4,738,210 USD | — | 6,210,306 USD | — | 4,523,454 USD | 4,523,454 USD | 2,989,697 USD | 2,989,697 USD |
| Total liabilitiesBalance sheet | 437,091 USD | — | — | — | — | — | 1,572,366 USD | 1,572,366 USD |
| Capital expendituresCash flow statement | — | 40,816 USD | — | 40,816 USD | — | — | — | 24,646 USD |
| Financing cash flowCash flow statement | — | 6,518,105 USD | — | 6,518,105 USD | — | — | — | 6,046,163 USD |
| Investing cash flowCash flow statement | — | -86,097 USD | — | -59,008 USD | — | — | — | -243,019 USD |
| Operating cash flowCash flow statement | — | -4,782,990 USD | — | -3,147,970 USD | — | — | — | -10,450,387 USD |
| Report source | Open report ↗ Published: 07/13/2026 | Open report ↗ Published: 07/13/2026 | Open report ↗ Published: 07/13/2026 | Open report ↗ Published: 04/13/2026 | Open report ↗ Published: 07/13/2026 | Open report ↗ Published: 04/13/2026 | Open report ↗ Published: 07/13/2026 | Open report ↗ Published: 11/28/2025 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.